Article
pUDK-HGF Gene Therapy to Relieve CLI Rest Pain and Ulcers: A Phase II, Double-Blind, Randomized Placebo-Controlled Trial
2020-11-05
Abstract excerpt
<h4>Background: </h4> Critical limb ischemia (CLI) has become a global problem. Less invasive therapy is needed. Hepatocyte growth factor (HGF) is one of the most potent angiogenic protein and the plasmid encoding human hepatocyte growth factor (HGF) is considered to be the most promising gene therapy for CLI.MethodsWe conducted a randomised, double-blind, placebo-controlled trial to assess the efficacy and safety...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 830e4516-ecac-5bea-8aa6-cb486a34fea7
- DOI
- 10.21203/rs.3.rs-101447/v1
